Cancer Gene Therapy Market to Reach $13.58 Billion by 2030, Driven by Growing Demand for Pain-Free Treatment and Increased Healthcare Expenditure

Strategic Insights -

The cancer gene therapy market is experiencing significant growth, driven by the growing demand for painless treatment at lower cost, coupled with increasing aesthetic consciousness among the population, significantly increasing the demand for cancer gene therapy across different parts of the globe. The global market for cancer gene therapy was valued at USD 4.52 Billion in 2024 and is expected to reach USD 13.58 Billion by 2030, rising at a CAGR of 20.12 percent.

Key Takeaways:

  • The cancer gene therapy market is driven by the growing demand for painless treatment at lower cost and increasing aesthetic consciousness among the population, with an estimated 66,470 people (48,520 men and 17,950 women) being diagnosed with head and neck cancer in the United States in 2022.
  • The rising global burden of cancer, with cancer being a leading cause of death globally, responsible for nearly 10 million deaths in 2020, is a fundamental driver of the cancer gene therapy market.
  • Gene therapy offers a transformative approach to cancer treatment by directly targeting the genetic root of disease, with companies like Celgene Inc. and Merck KGaA developing and marketing cancer gene therapies.
  • High cost and limited access to gene therapy are key challenges facing the global cancer gene therapy market, with approved therapies priced between $350,000 to $500,000 per patient in markets like the U.S. and Europe.
  • The expansion of personalized cancer gene therapy is a major trend in the global cancer gene therapy market, with advances in genomics and next-generation sequencing enabling detailed characterization of cancer at the molecular level.
  • Global governments are actively investing in precision oncology, with the U.K. launching the Genomic Medicine Service within the NHS and the U.S. supporting the Precision Medicine Initiative.

Statistics:

  • The cancer gene therapy market was valued at USD 4.52 Billion in 2024 and is expected to reach USD 13.58 Billion by 2030, rising at a CAGR of 20.12 percent.
  • An estimated 66,470 people (48,520 men and 17,950 women) will be diagnosed with head and neck cancer in the United States in 2022.
  • Cancer is a leading cause of death globally, responsible for nearly 10 million deaths in 2020.
  • Approved cancer gene therapies are priced between $350,000 to $500,000 per patient in markets like the U.S. and Europe.

Sources:

  • "Cancer Gene Therapy Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F" by ResearchAndMarkets.com
  • World Health Organization (WHO) - "Cancer" (2020)
  • U.S. National Cancer Institute (NCI) - "Cancer Moonshot" (2020)
  • 21st Century Cures Act (2016)
  • Precision Medicine Initiative (2015)